The Australian Diabetes Society (ADS) is pleased to announce a call for applications for the 2018 ADS-Servier Diabetes Research Grants in Memory of Barry Young. The grant has been made possible through the generosity of Servier Laboratories Australia who have strongly supported the national diabetes priorities for many years.
Grant proposals must involve improvement of patient care and be consistent with the following identified national diabetes priorities to:
Projects must be applicable to diabetes care in Australia. The value of the grant may vary but it is anticipated that one grant will be offered, up to the value of A$50,000. The Principal Investigator must be a financial member of the ADS for at least one year at the time of application. Grants are to be submitted in the format: title, background, aims, methods, expected contribution to patient care, project plan, ethics approval (if relevant) and a detailed budget. Grant applications must be NO longer than four A4 pages with a minimum font size of 12. A brief report on the outcome of the work (which may be posted on ADS website) must be submitted to ADS and the awardees are expected to present their work at an ADS/ADEA Annual Scientific Meeting within 18 months of completion.
Please note: All applications will be screened by the Grant Review Committee which will be comprised of members of the Australian Diabetes Society Council and a representative of Servier Laboratories, before proceeding to external peer review. The Grant Review Committee reserves the right to reject any application prior to review if it does not comply with the criteria or the purpose of this grant scheme. There will be no feedback provided to unsuccessful applications.
Grant applications are to be submitted by email to:
A/Professor Sof Andrikopoulos
Chief Executive Officer
Australian Diabetes Society
Applicants are encouraged to apply for an ADS-sponsored one-year fellowship of $80,000 plus a travel allowance of up to $5,000.
* Applicant must be a financial ADS member for at least one year at the time of application
* The fellowship must commence by 30 June, 2018
* The applicant must be less than six years post-doc as of December, 2017
* The applicant must provide a statement that the fellowship is for salary support and is not for support toward a grant/consumables
* The applicant must notify the ADS of any fellowship applications currently pending (e.g. NHMRC)
* The fellow must take up a position in Australia for the duration of the award
* The project must be diabetes related
Conditions of the award:
* Award of PhD is not required at the time of application but PhD must be awarded by the time of commencement
* The award cannot be held in conjunction with another major fellowship. If the highest ranking applicant is successful with another fellowship application or grant providing salary support, they must notify the ADS and the next suitable candidate will be offered the award
* The ADS reserves the right not to allow the fellowship if there is no eligible applicant of sufficiently high standard
* The fellow must present their work at the 2018 or 2019 ADS Annual Scientific Meeting
* The fellow must acknowledge the ADS in publications related to the work
To apply please compete the online application form which can be downloaded from ADS Skip Martin Early Career Fellowship Online Application Form
We anticipate the winner will be announced in January 2018.
The Australian Diabetes Society Council would like to congratulate the following ADS memebrs as winners of the following Young Investigator & Poster Awards:
2017 ADS Pincus Taft Young Investigator Award (Best Basic Science Oral Presentation)
2017 ADS President’s Young Investigator Award (Best Clinical Research Oral Presentation)
2017 ADS Basic Science Poster Award Rodrigo Carlessi
2017 ADS Clinical Research Poster Award Emily Meyer
We would like to invite you to be a part of the inaugural Australasian Diabetes Advancements and Technologies Summit (ADATS) 2017.
To view the ADATS program please click here to visit our website.
Friday 20 October 2017
PARKROYAL Darling Harbour, 150 Day St, Sydney, NSW
For more information please email to email@example.com
The theme for WDD 2017 is Women and Diabetes.
The World Diabetes Day 2017 campaign will promote the importance of affordable and equitable access for all women at risk for or living with diabetes to the essential diabetes medicines and technologies, self-management education and information they require to achieve optimal diabetes outcomes and strengthen their capacity to prevent type 2 diabetes.
There are currently over 199 million women living with diabetes and this total is projected to increase to 313 million by 2040. Gender roles and power dynamics influence vulnerability to diabetes, affect access to health services and health seeking behavior for women, and amplify the impact of diabetes on women.
Diabetes is the ninth leading cause of death in women globally, causing 2.1 million deaths each year. As a result of socioeconomic conditions, girls and women with diabetes experience barriers in accessing cost-effective diabetes prevention, early detection, diagnosis, treatment and care, particularly in developing countries. Socioeconomic inequalities expose women to the main risk factors of diabetes, including poor diet and nutrition, physical inactivity, tobacco consumption and harmful use of alcohol.
Two out of every five women with diabetes are of reproductive age, accounting for over 60 million women worldwide. Women with diabetes have more difficulty conceiving and may have poor pregnancy outcomes. Without pre-conception planning, type 1 and type 2 diabetes can result in a significantly higher risk of maternal and child mortality and morbidity.
Approximately one in seven births is affected by gestational diabetes (GDM), a severe and neglected threat to maternal and child health. Many women with GDM experience pregnancy related complications including high blood pressure, large birth weight babies and obstructed labour. A significant number of women with GDM also go on to develop type 2 diabetes resulting in further healthcare complications and costs.
Stigmatisation and discrimination faced by people with diabetes are particularly pronounced for girls and women, who carry a double burden of discrimination because of their health status and the inequalities perpetrated in male dominated societies. These inequalities can discourage girls and women from seeking diagnosis and treatment, preventing them from achieving positive health outcomes.
Visit the International Diabetes Federation for more information at http://worlddiabetesday.org/about-wdd.html
The Australian Diabetes Society (ADS) and the Australian Diabetes Educators Association (ADEA) reaffirm their strong partnership as leaders in diabetes education, management and research at the 2017 Annual Scientific Meeting.
The exciting and innovative program will bring together national and international experts to promote the exchange of the latest clinical practices and cutting edge research in diabetes. State-of-the-Art lectures, free communication sessions and clinical and scientific educational symposia, will all be appreciated by the 2018 attendees.
Wednesday 22 August to Friday 24 August 2018
Please be advised the 2018 ADS/ADEA ASM will be extended into Friday afternoon. If you are planning to fly home on the Friday, please make suitable flight arrangements to ensure you don't miss the closing plenary session concluding at 3:30pm.
Registrations will open for the 2018 ADS/ADEA Annual Scientific Meeting in Feb-March 2018. Please visit the ASM website at http://www.diabetescongress.com.au/ to register.
Abstract Submission is currently not open for the 2018 ADS/ADEA Annual Scientific Meeting. ADS categories for abstract submission are Basic Science or Clinical Science. Abstract submission closing date TBC. To submit an abstract please vist the ASM website at http://www.diabetescongress.com.au/
To make enquiries into sponsoring or exhibiting at the 2018 ASM, please contact Think Business Events at firstname.lastname@example.org
Category 2 RACGP QI&CPD points are available for GPs that attend certain sessions within the conference. The eligible sessions for 2018 will be made available closer to the time. There will be a form available at the registration desk at the conference for GPs to complete and to then receive the points.
The 2018 ADS Annual General Meeting will be held on Thursday 23 August from 12:15pm to 1:00pm at the Adelaide Convention Centre, SA. All financial members of the Australian Diabetes Society are welcome to attend the Annual General Meeting.
Think Business Events
Unit 17, 3 Westside Avenue
Port Melbourne VIC 3207
T +61 (0)3 9417 1350
F +61 (0)3 8610 2170
You can access our Annual Scientific Meeting site at http://www.diabetescongress.com.au/ or contact Think Business Events on 03 9417 1350 for any further details regarding the ASM.
Friday 24 August 2018 - 1:30pm to 5:30pm
Adelaide Convention Centre, SA
(Please Note: This Course is by Invitation Only which trainees must register via the ADS website at http://diabetessociety.com.au/grants-ads-turtle.asp to attend and is open for Advanced Trainees in Adult Endocrinology only. Registrations will not be accepted at the time of the ASM. Registration will open late May 2018)
From 1 April 2017, the Australian Government will provide fully subsidised continuous glucose monitoring (CGM) products to eligible children and young people aged under 21 years with type 1 diabetes.
Children and young people who experience significant challenges in managing their blood glucose levels, particularly those who have difficulty identifying symptoms of hypoglycaemia, will benefit the most from CGM technology.
This initiative allows families and children to better self-manage their blood glucose levels, reducing visits to emergency departments and missed school days.
Continuous glucose monitors will alert users or their parents/carers if glucose levels are getting too low or too high without the need for continuous finger prick tests, reducing stress and anxiety for the child and young person and their family.
To be eligible, the child or young person will need to be assessed by an authorised health professional to determine if they meet specific criteria and to ensure that the use of CGM is a suitable part of their diabetes management plan.
The authorised health professionals for CGM assessment are endocrinologists, credentialled diabetes educators, and other health professionals specialising in diabetes (physicians, paediatricians or nurse practitioners).
An expert CGM Advisory Group, including endocrinologists, credentialed diabetes educators, consumer experts and other diabetes stakeholder groups, has advised that the best clinical outcomes are achieved when CGM is used as part of an ongoing diabetes management plan. Authorised health professionals will also play a key role in assisting in the set up and operation of CGM devices for eligible children and young people not currently using CGM.
The Continuous Glucose Monitoring Eligibility Assessment form is available at www.ndss.com.au/cgm.
Further information about access to CGM products through the NDSS, please visit www.health.gov.au/ndss-cgm. You can also call the NDSS Helpline on 1300 136 588. Download the CGM Flow Chart for Health Professionals - PDF
Mervyn Kyi, Barbora Paldus, Natalie Nanayakkara, Michael Bennett, Rebecca Johnson, Catherine Meehan, Peter Colman
In 2015 the Australian Diabetes Society commissioned a working group to review and revise its position statement on scuba diving in persons with diabetes. The working group consisted of endocrinologists with an interest in type 1 diabetes, diving medical specialists, a recreational diver with diabetes and an advocate for people with type 1 diabetes.
A thorough literature review was performed and all available evidence was summarised and a new position statement was drafted. The new position statement was submitted to the ADS Council for approval.
The scope of this document is restricted to recreational (not professional) diving in line with the available evidence. It is also targeted at insulin-requiring (both type 1 and type 2) diabetes, as traditionally this group has been excluded from recreational diving. This document updates the ADS position statement in line with current evidence.
As part of World Diabetes Day (14 November, 2016), the Australian Diabetes Society has launched a new interactive website aimed at improving the lives of people living with type 2 diabetes.
The T2D treatment website is the first of its kind in Australia to offer health-care clinicians a user-friendly, interactive tool to assist them in determining the best treatment option for their patients. The launch of the website follows the release of a revised position statement by the ADS entitled, ‘A new blood glucose management algorithm for type 2 diabetes’.
This initiative involved the support of groups including the National Association of Diabetes Centres (NADC), Diabetes Australia (DA), the National Prescribing Service (NPS) and the Royal Australian College of General Practitioners (RACGP).
Please visit http://t2d.diabetessociety.com.au to access the T2D treatment website.
The blood glucose management algorithm for type 2 diabetes outlines the risks, benefits and costs of available therapies and provides an approach for how to incorporate older and newer agents.
Control of blood glucose levels in people with type 2 diabetes has clear benefits for preventing microvascular complications and potential benefits for reducing macrovascular complications and death.
Treatment needs to be individualised for the person with diabetes.
This should start with selection of the appropriate blood glucose and HbA1c targets, taking into account life expectancy and the wishes of the person with diabetes. A range of recently available therapies have added to our range of options for controlling blood glucose levels but this has made the clinical pathway for managing diabetes more complicated.
To assist with clinical decision making, in 2014 the Australian Diabetes Society council appointed an expert working group to draft a position statement with a focus on the results of recent randomised clinical trials. The original statement was reviewed by the ADS council (September 2014) and then sent to all ADS members for comment before publication in the Medical Journal of Australia (December 2014). In light of new randomised clinical trial evidence the statement and algorithm was updated (December, 2016).
Download the updated (December, 2016) full version of the ADS A New Blood Glucose Management Algorithm for Type 2 Diabetes Position Statement - PDF (Posted: December, 2016)
The Australasian Diabetes Data Network (ADDN) is an initiative of the Juvenile Diabetes Research Foundation (JDRF) supported by the Australasian Paediatric Endocrine Group (APEG) and the Australian Diabetes Society (ADS) to build long term clinical research capacity in Australia for people with diabetes.
ADDN has established Australia’s first national clinical research diabetes database, collecting clinical information from people with type 1 diabetes and connecting the data on an integrated, secure, custom-built platform. This rich data resource includes national-level information about type 1 diabetes, available to researchers within strict ethical and governance boundaries.
The database currently contains clinical data from children and adolescents with diabetes from seven specialist paediatric public tertiary centres across Australia. With planned expansion to adult centres, ADDN will extend its data capture and provide richer and more complete information about the natural history, clinical progression and most effective treatment regimens for all people living with type 1 diabetes.
For more information, visit the ADDN website at http://www.addn.org.au/
Obesity is a complex and multi-factorial chronic disease with genetic, environmental, physiological and behavioural determinants that requires long-term care. In 2014-15, 63.4% of Australians aged 18 years and over were above normal weight, with 27.9% being obese. Obesity is associated with a broad range of complications including type 2 diabetes, cardiovascular disease, dyslipidaemia, sleep apnoea, osteoarthritis, and certain types of cancers, which significantly impair quality of life. Obesity and its related complications place a considerable financial burden on Australia. In 2014-15, the direct and indirect costs of obesity were estimated at $ 8.65 billion.
This statement has been developed by a working group with representatives from the Australian Diabetes Society, the Australian and New Zealand Obesity Society and the Obesity Surgery Society of Australian and New Zealand.
The aims of the document are to:
1) Assist general practitioners (GPs) in treatment decisions for non-pregnant adults with obesity
2) Provide a practical clinical tool to guide the implementation of existing guidelines for the treatment of obesity in the primary care setting in Australia.
Download the full version of the Australian Obesity Management Algorithm - PDF (Posted: October, 2016)
Ramadan will begin on Saturday 27 May 2017 and ends on Sunday 25 June 2017. To assist health professionals, religious leaders and people with diabetes who fast during Ramadan, the Australian Diabetes Society (ADS), in conjunction and consultation together with the International Diabetes Federation (IDF) and the Diabetes and Ramadan International Alliance (DAR), have produced the following brochures:
In February 2017, the ADS and the NADC joined representatives from the Diabetes and Ramadan (DaR) International Alliance at this first-ever symposium in Australia. The event was an initiative of the Department of Endocrinology and Metabolism at Concord Repatriation General Hospital.
The event promoted the new IDF-DaR Diabetes and Ramadan Practical Guidelines, which provide healthcare professionals with important information to assist them in supporting patients during Ramadan.
A copy of the guidelines can be downloaded from the IDF website at http://www.idf.org/guidelines/diabetes-in-ramadan.
Many thanks to Sanofi who sponsored the production of the symposium videos. Please click the following link http://nadc.net.au/video/ to access the symposium videos via the National Association of Diabetes Centres (NADC) website and share with your colleagues.
The Council of Therapeutic Advisory Groups (CATAG, www.catag.org.au) has updated and released the following document.,‘Overseeing biosimilar use. Guiding Principles for the governance of biological and biosimilar medicines in Australian hospitals’ Version 2 (September 2016). CATAG is cognisant the governance and management of biosimilars medicines is an evolving area and has reviewed its guidance in the context of national and international developments, including the outcome of the TGA review. The purpose of the Guiding Principles is to provide guidance for good governance and decision-making in relation to the use of biological therapies within Australian public hospitals. The guidance is intended to provide an overall framework, which is encouraged to be implemented locally. The guidance consists of nine Guiding Principles, which address the importance of governing the selection, prescription, switching, patient involvement, monitoring and communication of biologic/biosimilar use. The updated version 2 of the biosimilar Guiding Principles includes two significant changes. The document is available through the CATAG website at www.catag.org.au and can be downloaded as a PDF.
While many factors contribute to safety on the road, driver health and fitness to drive is an important consideration. Drivers must meet certain medical standards to ensure their health status does not unduly increase their crash risk. Assessing Fitness to Drive, a joint publication of Austroads and the National Transport Commission (NTC), details the medical standards for driver licensing for use by health professionals and driver licensing authorities. The standards are approved by Commonwealth, state and territory transport ministers. In October 2016, new medical standards come into effect for drivers of private and commercial vehicles. The NTC website provides information for health professionals, employers, heavy vehicle drivers, commercial drivers and private vehicle drivers. Please click on the link to download the free electronic pdf version at https://www.onlinepublications.austroads.com.au/items/AP-G56-16
TOUJEO® (300 units/mL) will be available in Australia as a private prescription for the treatment of diabetes mellitus in adults as of 1 December 2016.
Toujeo® SoloStar® is a prefilled pen that contains a longer-acting1 formulation of insulin glargine (300 units/mL) compared with Lantus® (insulin glargine 100 units/mL). Toujeo is designed for once-daily subcutaneous administration. Toujeo (300 units/mL) will appear in commonly used script writing software.
Toujeo is not currently available on the Pharmaceutical Benefits Scheme (PBS) and will not be available at a PBS-subsidised price, so patients will incur out of pocket costs. We recommend advising patients to check with their pharmacist to determine the cost of having their Toujeo prescription dispensed.
It is important to note that this strength of insulin glargine (300 units/mL [Toujeo]) is not bioequivalent and therefore not automatically interchangeable to other basal insulins and will require dose adjustment.
For information about price, guidance on how to initiate a patient on Toujeo and to access an educational leaflet for patients, please download these resources via the following links (Private Supply Notice - PDF / Patient Carer Guide - PDF / Healthcare Professional Guide - PDF)
To find out more about Toujeo, visit the website at https://www.toujeo.com.au
The TGA has issued an update on the availability status of Metformin.
The following products are now available:
The current status of shortages and affected products is outlined in the table below:
CHEMMART METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack
Apotex Pty Ltd
APO-METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack
Apotex Pty Ltd
TERRY WHITE CHEMISTS METFORMIN XR 500 metformin hydrochloride 500 mg modified release tablet blister pack
Apotex Pty Ltd
METEX XR metformin hydrochloride 500 mg extended release tablet blister pack
Arrow Pharma Pty Ltd
The TGA also advises pharmacists that, if they are unable to obtain Metformin extended release products that are currently available through their regular wholesaler, they should contact an alternative wholesaler to try to secure stock.
Novo Nordisk Pharmaceuticals Pty Ltd is recalling certain batches of GlucaGen® HypoKit due to a small number of needles becoming detached from the pre-filled syringe supplied in the GlucaGen® HypoKit
Novo Nordisk Pharmaceuticals Pty Ltd is recalling for batches of GlucaGen® HypoKit in Australia. GlucaGen® HypoKit is used for the treatment of severe hypoglycaemic reactions which may occur in the management of diabetic patients receiving insulin or oral hypoglycaemic agents. This action has been undertaken following consultation with the Therapeutic Goods Administration (TGA). Novo Nordisk conducted an investigation showing a small number (0.006%) of needles from certain batches may become detached from the pre-filled syringe supplied during use. Despite the very low risk to patient safety, Novo Nordisk is recalling all products in the affected batches from wholesalers, pharmacies and patients in Australia.
The recalled GlucaGen® HypoKit batch numbers and expiry date in Australia are:
Note that community and hospital pharmacies will also be contacted and requested to follow up with patients they have supplied since February 2016 and will be asked to return any stock they hold from affected batches. Formal notification has also been sent to mainstream national media, professional diabetes/endocrine societies, RACGP, RACP and diabetes patient associations. If patients have a GlucaGen® HypoKit from an affected batch they are to return it to their pharmacy. They will be given a free replacement either immediately (if the pharmacy has unaffected stock available) or within a few days (if the pharmacy has to await resupply). If the pharmacy does not receive a replacement immediately, the patient is to retain their GlucaGen® HypoKit until the replacement can be provided, as the likelihood of a detached needle is very low. Importantly, if you are in possession of GlucaGen® HypoKit products with batch numbers NOT mentioned above there is NO concern and you can be confident that the products will work as prescribed. Further information: NovoCare® Customer Care Centre Phone: 1800 668 626 Email: email@example.com Website: www.novonordisk.com.au
The ADS has recently endorsed international guidelines that recommend metabolic surgery for patients with type 2 diabetes and class III (BMI ≥40 kg/m2) obesity and patients with type 2 diabetes with class II (BMI 35.0–39.9 kg/m2) obesity who have had inadequate glycaemic control with lifestyle and pharmacotherapy.
Download the full version of the 'Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations' Guidelines - PDF (Posted: June, 2016)
The 2017 Australian Diabetes Society Membership Fee Renewals are now overdue. Please ensure that the ADS Secretariat has all the correct mailing and contact details, particularly email addresses, as we rely on these to maintain contact with you and keep you informed of ADS activities. The 2017 ADS Subscription period is from 1 July 2017 to 30 June 2018. Please contact the ADS secretariat at firstname.lastname@example.org for membership enquiries.
“Enhancing Your Consulting Skills: Supporting self-management and optimising mental health in people with type 1 diabetes” is designed for trainees in Adult Endocrinology, their supervisors and other interested health professionals. The resource includes topics such as information giving, health literacy, facilitating practical skills acquisition, and promoting behaviour change. It also explores the emotional, psychological and psychiatric issues that can impact on the quality of life of people with type 1 diabetes.
“Enhancing Your Consulting Skills” was developed by the Australian Diabetes Society for the National Diabetes Services Scheme. It is now available in electronic format through the ADS website at: [http://diabetessociety.com.au/download-request.asp]. It can be downloaded free of charge for individual use. Please Note that you will be required to submit a request for download and obtain your password prior to receiving the download link. Hard copies of the resource are available from the ADS Secretariat.
From 1 July 2016 some important changes are happening to the National Diabetes services Scheme (NDSS). There are no changes to the types of products available under the NDSS, but the way people access these products may change. People will still be able to access NDSS products through their local participating community pharmacy access point. In fact the Federal Government wants to extend the number of community pharmacies that provide NDSS products to make it more convenient for people with diabetes. NDSS products will no longer be available through Diabetes Australia (DA) or state and territory diabetes organisations. This means people will no longer be able to order products via the Diabetes Australia shops, the NDSS 1300 number or via the website. Diabetes Australia and state and territory diabetes organisations will instead focus efforts on continuing to provide education services for people with diabetes. There will be no changes to NDSS education services funded by the Government - in fact the Government will be increasing funding to expand education and support available to people with diabetes. Community Pharmacies have made up more than 90% of all NDSS access points in Australia for over ten years, so people can be confident that if they have not accessed pharmacy before for this, they will receive a high level of service.
The Australian Government has developed and released a new National Diabetes Strategy to update and priorities the national response to diabetes across all levels of government. The Australian National Diabetes Strategy 2016-2020 (the Strategy) is a high-level document that contains a number of goals and potential areas for action that provide a range of ideas for implementation to achieve each goal. This presents a range of opportunities for jurisdictions to partner with the Commonwealth to develop and support approaches for diabetes prevention and control. The Strategy was endorsed by the Australian Health Ministers Advisory Council (AHMAC) on 2 October 2015, noted by the COAG Health Council on 6 November 2015, and publically released 13 November 2015. An implementation plan will be developed in consultation with jurisdictions through AHMAC to consider the ways to direct funding and other resources and proposed measures to evaluate the progress of the Strategy. Engagement and support from jurisdictions will facilitate a coordinated approach to diabetes across governments and ensure there is broad benefit from the Strategy. The Strategy has been informed by the expert advice of the National Diabetes Strategy Advisory Group and consultations with key stakeholders and the community. The Australian Government provides support to people with diabetes through Medicare and a range of programs and this new Strategy will not replace or override existing processes. This Strategy aims to better coordinate health resources across the sector to where they are needed most. The Australian National Diabetes Strategy document is available from the Department of Health's website at http://www.health.gov.au/internet/main/publishing.nsf/Content/nds-2016-2020 Media Release Statement by Health Minister; the Hon Sussan Ley MP on Australia delivers new National Diabetes Strategy on World Diabetes Day
The Australian Diabetes Society endorses Endocrinology, Diabetes & Metabolism Case Reports
Endocrinology, Diabetes & Metabolism Case Reports is a unique, open access resource that publishes and links together case reports, enabling practitioners to communicate findings, share knowledge and convey medical experiences efficiently and effectively; furthering both medical education and clinical practice. The search and browse functionality enables fluid navigation between case reports, facilitating discovery, connections and comparisons; making it the go-to resource across all the many disciplines intersecting with endocrinology, diabetes and metabolism.
Members of the Australian Diabetes Society receive a 20% discount on the open access publishing charge when publishing case reports in Endocrinology, Diabetes & Metabolism Case Reports (submit online via www.edmcasereports.com).
Please click on the PDF link to download and view the member flyer - PDF